Innostellar Biotherapeutics Co.,Ltd
Quick facts
Phase 2 pipeline
- Aflibercept intravitreal injection · Ophthalmology
Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: